

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2005-05-02** | Period of Report: **2005-04-22**
SEC Accession No. **0001104659-05-019648**

([HTML Version](#) on [secdatabase.com](#))

ISSUER

ABBOTT LABORATORIES

CIK: **1800** | IRS No.: **360698440** | State of Incorporation: **IL** | Fiscal Year End: **1231**
SIC: **2834** Pharmaceutical preparations

Business Address
100 ABBOTT PARK ROAD
D-322 AP6D
ABBOTT PARK IL 60064-3500
8479376100

REPORTING OWNER

Tyree James L

CIK: **1324991**
Type: **3** | Act: **34** | File No.: **001-02189** | Film No.: **05790969**

Mailing Address
100 ABBOTT PARK ROAD
ABBOTT PARK IL 60064-6400
Business Address
(847) 937-6100

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: 02/28/2011
 Estimated average burden
 hours per response 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Tyree James L			2. Date of Event Requiring Statement (Month/Day/Year) 04/22/2005		3. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Senior Vice President		5. If Amendment, Date Original Filed (Month/Day/Year)	
100 ABBOTT PARK ROAD					6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person	
(Street)						
ABBOTT PARK, IL 60064-6400						
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	52,503	D	
Common shares without par value	1,087 ⁽¹⁾	I	profit sharing trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy) ⁽²⁾	04/13/1999	06/29/2007	Common shares	2,468	\$40.5054	D	
Option (right to buy) ⁽²⁾	07/12/1999	06/29/2007	Common shares	3,180	\$44.321	D	
Option (right to buy) ⁽²⁾	02/12/2000	02/11/2009	Common shares	12,768	\$42.4978	D	
Option (right to buy) ⁽²⁾	10/14/1999	12/30/2007	Common shares	3,958	\$49.5463	D	
Option (right to buy) ⁽²⁾	01/13/2000	06/29/2007	Common shares	2,519	\$39.6784	D	
Option (right to buy) ⁽²⁾	02/09/2002	02/08/2011	Common shares	22,876	\$45.4488	D	
Option (right to buy) ⁽²⁾	06/01/2002	05/31/2011	Common shares	15,960	\$48.1225	D	
Option (right to buy) ⁽²⁾	02/15/2003	02/14/2012	Common shares	42,561	\$53.625	D	
Option (right to buy) ⁽²⁾	11/10/2002	12/30/2007	Common shares	8,422	\$49.2456	D	

Option (right to buy) ⁽²⁾	11/10/2002	06/29/2007	Common shares	6,069	\$49.2456	D	
Option (right to buy) ⁽²⁾	06/03/2003	06/29/2007	Common shares	2,429	\$41.1445	D	
Option (right to buy) ⁽²⁾	02/14/2004	02/13/2013	Common shares	1	\$33.2314	D	
Option (right to buy) ⁽²⁾	02/14/2006	02/13/2013	Common shares	17,734	\$33.2314	D	
Option (right to buy) ⁽²⁾	11/30/2003	02/10/2010	Common shares	10,276	\$40.9283	D	
Option (right to buy) ⁽²⁾	06/02/2004	06/29/2007	Common shares	153	\$41.5392	D	
Option (right to buy) ⁽²⁾	06/02/2004	02/10/2010	Common shares	7,493	\$41.5392	D	
Option (right to buy) ⁽²⁾	06/24/2004	02/12/2008	Common shares	4,549	\$43.5128	D	
Option (right to buy) ⁽²⁾	02/20/2005	02/19/2014	Common shares	10,640	\$41.0317	D	
Option (right to buy) ⁽²⁾	02/20/2006	02/19/2014	Common shares	10,641	\$41.0317	D	
Option (right to buy) ⁽²⁾	02/20/2007	02/19/2014	Common shares	10,639	\$41.0317	D	
Option (right to buy) ⁽²⁾	12/25/2004	02/13/2013	Common shares	13,853	\$41.95	D	
Option (right to buy) ⁽²⁾	06/28/2005	02/13/2013	Common shares	1,562	\$46.42	D	
Option (right to buy) ⁽²⁾	06/28/2005	02/12/2008	Common shares	9,217	\$46.42	D	
Option (right to buy) ⁽³⁾	02/18/2006	02/17/2015	Common shares	11,600	\$46.34	D	
Option (right to buy) ⁽³⁾	02/18/2007	02/17/2015	Common shares	11,600	\$46.34	D	
Option (right to buy) ⁽³⁾	02/18/2008	02/17/2015	Common shares	11,600	\$46.34	D	
Option (right to buy) ⁽³⁾	09/17/2005	02/13/2013	Common shares	14,811	\$45.66	D	

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of April 27, 2005.
2. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.
3. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.

Signatures

John A. Berry, by power of attorney for James L. Tyree

** Signature of Reporting Person

05/02/2005

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned constitutes and appoints LAURA J. SCHUMACHER, JOHN A. BERRY and DEBORAH K. KOENEN, and each of them individually, as the undersigned' s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned' s name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Dated: 4-25-2005

/s/ James L. Tyree
Signature of Reporting Person

James L. Tyree
Senior Vice President

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-6400
